

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence, including listed enclosures is being electronically transmitted in Portable Document Form (PDF) through EFS-Web via Hyper Text Transfer Protocol to the United States Patent and Trademark Office's Patent Electronic Business Center on:

Dated:

Signed:

November 5, 2009
[Signature]

PATENT

Attorney Docket No.: 101961-5108-US
Client Ref. No.: 7935.204US
(NEO00073US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert Bayer

Application No.: 09/855,320

Filed: May 14, 2001

For: In Vitro Modification of
Glycosylation Patterns of Recombinant
Glycopeptides

Customer No.: 43850

Confirmation Number: 1113

Examiner: RAGHU, Ganapathiram

Art Unit: 1652

LETTER TO EXAMINER AND STATEMENT OF
RELATEDNESS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In view of *Dayco Products Inc. v. Total Containment Inc.*, 66 USPQ2d 1801 (Fed. Cir. 2003) and *McKesson Information Solutions Inc. v. Bridge Medical Inc.*, 82 USPQ2d 1865 (Fed. Cir. 2007) and in satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and as required by M.P.E.P. § 2001.06(b), Applicants note that the present application is related to the following patent applications:

08/102,385; 08/215,727; 08/312,387; 08/446,875; 08/447,435; 08/447,783;
08/478,140; 08/683,426; 08/683,458; 08/745,840; 08/878,360; 09/333,412; 09/338,943;
10/007,267; 10/096,129; 10/109,498; 10/198,806; 10/219,197; 10/287,994; 10/360,770;
10/360,779; 10/391,035; 10/410,897; 10/410,913; 10/410,930; 10/410,945; 10/410,962;
10/410,980; 10/410,997; 10/411,012; 10/411,026; 10/411,037; 10/411,043; 10/411,044;
10/411,049; 10/485,892; 10/492,261; 10/497,283; 10/497,284; 10/530,972; 10/549,445;

10/549,520; 10/549,528; 10/552,896; 10/556,094; 10/565,331; 10/576,506; 10/579,620;
10/579,621; 10/581,538; 10/585,385; 10/586,166; 10/609,701; 10/654,528; 10/997,405;
11/033,365; 11/102,497; 11/144,223; 11/166,028; 11/166,404; 11/183,205; 11/183,218;
11/339,752; 11/396,215; 11/402,105; 11/404,266; 11/440,839; 11/580,669; 11/584,743;
11/632,005; 11/644,014; 11/645,839; 11/652,467; 11/656,643; 11/657,441; 11/658,218;
11/659,153; 11/659,942; 11/664,199; 11/665,908; 11/701,949; 11/714,874; 11/781,885;
11/781,888; 11/781,896; 11/781,900; 11/781,902; 11/792,610; 11/794,555; 11/794,560;
11/843,588; 11/845,175; 11/866,969; 11/867,553; 11/910,958; 11/914,104; 11/915,239;
11/917,772; 11/934,700; 11/981,483; 11/982,273; 11/982,444; 12/060,383; 12/064,012;
12/066,619; 12/092,563; 12/101,389; 12/152,587; 12/184,956; 12/201,705; 12/302,167;
12/371,156; 12/418,530; 12/439,221; 12/443,428; 12/444,380; and 12/496,595.

Further in view of *Larson Mfg. Co. v. Aluminart Products Ltd.* No. 2008-1096, - 1174 (Fed. Cir. March 18, 2009), courtesy copies of the Office Actions received by applicants and/or their representatives as of the date of submission of this document in the abovementioned copending applications and other related applications are attached unless previously submitted.

However, the Examiner is encouraged to review the art made of record, any Office Action, and any Notice of Allowance in the above-mentioned related application. Applicants assume that due to the ease of review on PAIR by the Examiner, Applicant need not submit copies of the individual Office Actions and/or Notices of Allowance. With respect to any copending applications listed above, Applicants assume that the Examiner is aware that prosecution is ongoing in said cases, and that the Examiner will continue to evaluate these cases as needed.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0310. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Appl. No. 09/855,320

Respectfully submitted,



Ada O. Wong
Reg. No. 55,740

MORGAN, LEWIS & BOCKIUS, LLP
One Market, Spear Street Tower
San Francisco, California 94105
Direct Dial: 415.442.1490
Tel: 415.442.1000
E-Fax: 415.442.1001
E-mail: awong@morganlewis.com
ATTACHMENTS

Filed under 37 CFR 1.34

DB2/21407493.1